Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Hepatitis B Vaccination With or Without Imiquimod in Cirrhotic Non‑Responders
2024-514605-61-00Phase 2Completed
- Sponsor
- CHRU Nancy
- Start
- Jun 2024
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Hepatitis B vaccine and imiquimod in hepatitis B (HBV) and Cirrhosis (3 arms), sponsored by CHRU Nancy. Primary endpoint: Seroprotection rate at Month 7. Started Jun 2024; status: completed.
02
Drugs
Hepatitis B vaccineimiquimod
03
Conditions
hepatitis B (HBV)Cirrhosis
Beyond the preview
Go deeper on 2024-514605-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514605-61-00.